Molecular & Translational Drug Discovery
G protein-coupled receptors (GPCRs) are the largest family of receptors and are responsible for regulating a range of physiological functions and pathology. As such, it is unsurprising that approximately 40% of marketed drugs target this receptor family. We utilize a variety of platforms, techniques and collaborations in order to progress GPCR discovery projects towards clinical development. Research in this laboratory covers a range of disciplines including structural biology, molecular pharmacology, cellular & native tissue pharmacology and translational biology.
Servier Discovery Program: Our portfolio includes multiple GPCR projects at differing stages of the drug discovery process, ranging from target validation through to lead optimisation. Our primary therapeutic areas of interest are Parkinson’s disease, metabolic and immuno-inflammatory disorders.
Neuropsychiatry Discovery: The lab has a significant research interest in disorders associated with the basal ganglia in the CNS, including projects studying the role of the orphan GPCRs and muscarinic acetylcholine receptors in schizophrenia, cognitive disorders and addiction.
For further information, please contact Chris Langmead.